Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597

Journal of Clinical Oncology

Volumn 21, Issue 8, 2003, Pages 1550-1555

  Masters, Gregory A ^a   Declerck, Lieven ^a   Blanke, Charles ^a   Sandler, Alan ^a   DeVore, Russell ^a   Miller, Kathy ^a   Johnson, David ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; INFORMED CONSENT; LUNG FUNCTION; LUNG SMALL CELL CANCER; LUNG TOXICITY; MEDICAL SOCIETY; NEUROTOXICITY; NEUTROPENIA; PATIENT CODING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; AGED; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; SMALL CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SMALL CELL; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037504528     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.130     Document Type: Article

References (22)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics. CA Cancer J Clin 52:23-47, 2002
2. Murren J, Glasten E, Pass H, et al: Small cell lung cancer, in Devita VT, Rosenberg SA, Hellman S (eds): Cancer: Principles and Practice of Oncology (ed 6). Philadelphia, PA, Lippencott-Raven, 2001, pp 983-1018
3. Devore R, Johnson DH: Chemotherapy for small cell lung cancer, in Pass HI, Mitchell JB, Johnson DH (eds): Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott Williams & Wilkins, 2000, p 923
4. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
5. Murray N, Livingston RB, Shepherd FA, et al: Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17:2300-2308, 1999
6. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease-The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office and the Lung Cancer Cooperative Group. J Clin Oncol 15:2090-2096, 1997
7. Schiller J, Kim K, Hutson P, et al: Phase II study of topotecan in patients with extensive stage small cell carcinoma of the lung: An Eastern Cooperative Group Trial. J Clin Oncol 14:2345-2352, 1996
8. Perez-Soler R, Glisson B, Lee JS, et al: Treatment of patients with small cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14:2785-2790, 1996
9. Von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658-667, 1999
10. Shepherd FA, Evans WK, MacCormick R, et al: Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 71:941-944, 1987
11. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1618, 1990
12. Giaccone G, Danadio M, Bonardi G, et al: Teniposide in the treatment of small cell lung cancer: The influence of prior chemotherapy. J Clin Oncol 6:1264-1269, 1988
13. Argiris A, Murren J: Advances in chemotherapy for small cell lung cancer: Single agent activity of newer agents. Cancer J 7:228-235, 2001
14. Noble S, Goa KL: Gemcitabine: A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54:447-472, 1997
15. Sandler AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:2791-2792, 2000
16. Yamaji Y, Nakamura H, Fujita T, et al: Remarkable difference in growth inhibitory effect of gemcitabine on various human lung cancer cell lines. Proc Am Assoc Cancer Res 36, 1995 (abstr 2424)
17. Cormier Y, Eisenhauer E, Muldal A: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC): A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5:283-285, 1994
18. Israel VP, Chansky K, Gandara D: Southwest Oncology Group trial S9718: A phase II study of gemcitabine plus cisplatin in patients with extensive small cell lung cancer. Proc Am Soc Clin Oncol 20:316a, 2001 (abstr 1262)
19. James LE, Rudd R, Gower NH, et al: A phase III randomized comparison of gemcitabine/carboplatin with cisplatin/etoposide in patients with poor prognosis small cell lung cancer. Proc Am Soc Clin Oncol 21:293a, 2002 (abstr 1170)
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Slat Assoc 53:457-481, 1958
21. Johnson DH: Management of small cell lung cancer: Current state of the art. Chest 116:525S-530S, 1999 (suppl)
22. van der Lee I, Smit EF, van Putten JWG, et al: Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 12:557-561, 2001